Key result
CTO revascularization linked to ~52% lower cardiac death vs. medical therapy in reduced LVEF.
Why the study?
The benefits of revascularization in patients with chronic total occlusion and reduced left ventricular ejection fraction remain controversial.
Does percutaneous coronary intervention reduce cardiac death compared to medical treatment in patients with chronic total occlusion and reduced left ventricular ejection fraction?
Cohort (n=369)
Does percutaneous coronary intervention reduce cardiac death compared to medical treatment in patients with chronic total occlusion and reduced left ventricular ejection fraction?
Successful percutaneous coronary intervention for chronic total occlusion is associated with long-term survival benefits, including reduced cardiac death, in patients with reduced LVEF compared to medical therapy alone.
Answers are grounded in this paper and cite their sources.
May support revascularization in CTO with reduced LVEF; leaves open need for randomized confirmation before practice change.
BACKGROUND: The benefits of revascularization in patients with chronic total occlusion (CTO) and reduced left ventricular ejection fraction (LVEF) remain controversial. PURPOSE: This study aimed to investigate the clinical impact of CTO revascularization in patients with reduced LVEF compared with those receiving medical treatment (MT). METHODS: In total, 369 consecutive patients diagnosed with CTO by coronary angiography were allocated to either the MT group ( n = 204) or the percutaneous coronary intervention (PCI, n = 165) group according to the treatment strategy. The 5-year clinical outcomes were compared between the two groups using a Cox proportional hazards model. RESULTS: After inverse probability treatment weighting analysis, the pseudo-sample sizes in the MT and PCI groups were 364 and 370, respectively. After a median 6-year follow-up period (interquartile range, 5.0-8.1 years), the incidence of cardiac death was higher in the MT and PCI groups, at 9.0 and 4.5%, respectively ( P = 0.019). Cardiac death following heart failure hospitalization occurred in 3.8 and 1.0%, respectively ( P = 0.017). In contrast, target vessel revascularization for CTO lesions was more frequent in the PCI group than in the MT group (11.5 and 22.7%, respectively, P < 0.001). In the inverse probability treatment weighting population, patients undergoing CTO revascularization had survival benefits for cardiac death [hazard ratio: 0.48 (95% CI, 0.26-0.88)] and cardiac death after heart failure hospitalization [hazard ratio: 0.27 (95% CI, 0.08-0.84)]. CONCLUSION: In patients with LV systolic dysfunction, particularly those with EF less than or equal to 40%, successful CTO revascularization is associated with long-term survival benefits. These results suggest that successful CTO revascularization is associated with reduced rates of cardiac death and death after hospitalization for heart failure.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) conducted a cohort in Chronic total occlusion with reduced left ventricular ejection fraction (n=369). Percutaneous coronary intervention (CTO revascularization) vs. Medical treatment was evaluated on Cardiac death (HR 0.48, 95% CI 0.26-0.88, p=0.019). In patients with chronic total occlusion and reduced LVEF, revascularization was associated with a lower incidence of cardiac death compared to medical treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: